{"seq": 1, "variant": "control", "cmd": "pm --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm - PubMed CLI tools for AI agents\n\nUsage: pm <command> [OPTIONS]\n\nCommands:\n  init        Initialize audit trail and cache (.pm/)\n  search      Search PubMed, return PMIDs\n  fetch       Fetch PubMed XML by PMIDs\n  parse       Parse PubMed XML to JSONL\n  filter      Filter JSONL articles by field patterns\n  cite        Fetch CSL-JSON citations\n  download    Download full-text PDFs\n  diff        Compare two JSONL files by PMID\n  audit       View audit trail and PRISMA report\n  quick       One-command search pipeline (outputs JSONL)\n\nExamples:\n  pm search \"CRISPR cancer\" | pm fetch | pm parse > results.jsonl\n  pm quick \"covid vaccine\" --max 50\n  pm filter --year 2024 --has-abstract < articles.jsonl\n\nUse 'pm <command> --help' for command-specific help.\n", "stderr": "", "elapsed_s": 0.286, "ts": 1771594447.3431592}
{"seq": 2, "variant": "control", "cmd": "pm search --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm search - Search PubMed and return PMIDs\n\nUsage: pm search [OPTIONS] \"search query\"\n\nOptions:\n  --max N        Maximum results to return (default: 10000)\n  --refresh      Bypass cache and re-fetch from PubMed\n  -h, --help     Show this help message\n\nOutput:\n  PMIDs to stdout, one per line\n\nExamples:\n  pm search \"CRISPR cancer therapy\"\n  pm search --max 100 \"machine learning\"\n  pm search \"covid vaccine 2024\" | pm fetch | pm parse > results.jsonl\n\nQuery syntax:\n  Uses PubMed query syntax. See:\n  https://pubmed.ncbi.nlm.nih.gov/help/#search-tags\n", "stderr": "", "elapsed_s": 0.305, "ts": 1771594457.18866}
{"seq": 3, "variant": "control", "cmd": "pm fetch --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm fetch - Fetch PubMed XML from E-utilities API\n\nUsage: echo \"12345\" | pm fetch > articles.xml\n       cat pmids.txt | pm fetch > articles.xml\n\nOptions:\n  -v, --verbose  Show progress on stderr\n  -h, --help     Show this help message\n\nInput:\n  PMIDs from stdin, one per line\n\nOutput:\n  PubMed XML to stdout\n\nFeatures:\n  - Batches requests (200 PMIDs per API call)\n  - Rate limits to ~3 requests/second\n  - Exits with error on network failure\n\nExamples:\n  echo \"12345\" | pm fetch > article.xml\n  cat pmids.txt | pm fetch > articles.xml\n  pm search \"CRISPR\" | pm fetch | pm parse > results.jsonl\n", "stderr": "", "elapsed_s": 0.38, "ts": 1771594463.2759116}
{"seq": 4, "variant": "control", "cmd": "pm parse --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm parse - Parse PubMed XML to JSONL\n\nUsage: cat articles.xml | pm parse [OPTIONS] > articles.jsonl\n       zcat articles.xml.gz | pm parse [OPTIONS] > articles.jsonl\n\nOptions:\n  -v, --verbose  Show progress on stderr\n  -h, --help     Show this help message\n\nOutput:\n  One JSON object per line (JSONL format) with fields:\n    pmid, title, authors, journal, year, date, doi, pmcid, abstract\n\nExamples:\n  cat pubmed.xml | pm parse > articles.jsonl\n  zcat pubmed25n0001.xml.gz | pm parse > articles.jsonl\n  cat pubmed.xml | pm parse --verbose > articles.jsonl 2>progress.log\n", "stderr": "", "elapsed_s": 0.258, "ts": 1771594468.4929848}
{"seq": 5, "variant": "control", "cmd": "pm filter --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm filter - Filter JSONL articles by field patterns\n\nUsage: pm parse | pm filter [OPTIONS]\n       cat articles.jsonl | pm filter [OPTIONS]\n\nFilter Options:\n  --year PATTERN      Year filter (exact, range, or open-ended)\n                      Examples: 2024, 2020-2024, 2020-, -2024\n  --journal PATTERN   Journal contains PATTERN (case-insensitive)\n  --journal-exact STR Journal equals STR exactly\n  --author PATTERN    Any author contains PATTERN (case-insensitive)\n  --has-abstract      Article has non-empty abstract\n  --has-doi           Article has DOI\n\nGeneral Options:\n  -v, --verbose       Show filter stats on stderr\n  -h, --help          Show this help\n\nExamples:\n  pm filter --year 2020- --journal nature --has-abstract\n  pm filter --author smith\n  pm filter --year 2020-2024\n\nNotes:\n  - Multiple filters combine with AND logic\n  - Malformed JSON lines are silently skipped\n", "stderr": "", "elapsed_s": 0.239, "ts": 1771594472.7720013}
{"seq": 6, "variant": "control", "cmd": "pm quick --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm quick - Quick PubMed search (outputs JSONL)\n\nUsage: pm quick [OPTIONS] \"search query\"\n\nOptions:\n  --max N         Maximum results (default: 100)\n  -v, --verbose   Show progress on stderr\n  -h, --help      Show this help message\n\nOutput:\n  JSONL to stdout (one article per line)\n\nExamples:\n  pm quick \"CRISPR cancer therapy\"\n  pm quick --max 20 \"machine learning diagnosis\"\n\nFor advanced filtering, use the full pipeline:\n  pm search \"query\" | pm fetch | pm parse | pm filter --year 2024\n", "stderr": "", "elapsed_s": 0.231, "ts": 1771594477.8782475}
{"seq": 7, "variant": "control", "cmd": "pm search \"metabolic tumor volume\" PSMA prostate", "exit_code": 0, "stdin_lines": 0, "stdout": "41703276\n41421031\n41281171\n41067860\n40788167\n40696478\n40610228\n40247813\n40137954\n39110196\n39082074\n38835182\n38718704\n38298510\n37940684\n37734840\n36140613\n35902300\n34439287\n33866336\n33586096\n33525456\n32948911\n32685010\n", "stderr": "", "elapsed_s": 0.746, "ts": 1771594500.1474109}
{"seq": 8, "variant": "control", "cmd": "pm search \"tumor volume\" PSMA PET prostate prognos*", "exit_code": 0, "stdin_lines": 0, "stdout": "41703276\n41679922\n41486328\n41421031\n41281171\n41211255\n41167722\n41164426\n41111086\n41071425\n41067860\n41021003\n40967759\n40939837\n40935613\n40851054\n40696478\n40551434\n40383857\n40278858\n40268875\n40166057\n40137954\n40113645\n40001235\n39961974\n39915125\n39313655\n39209284\n39110196\n39080696\n38949389\n38948055\n38835183\n38718704\n38705743\n38693454\n38563882\n38469242\n38453363\n38298510\n38050125\n37678927\n37573199\n37385221\n37332068\n37272956\n37070991\n36859618\n36333565\n36302658\n35738906\n35543629\n35453632\n35422442\n35045552\n35008315\n34439287\n34373733\n34359750\n34326127\n33866336\n32970216\n32948911\n32941400\n32685010\n30363462\n27229485\n", "stderr": "", "elapsed_s": 0.767, "ts": 1771594511.70296}
{"seq": 9, "variant": "control", "cmd": "pm search PSMA PET \"total tumor volume\" prostate cancer", "exit_code": 0, "stdin_lines": 0, "stdout": "41679922\n41486328\n41363980\n41353166\n41287510\n41219580\n41167722\n41111086\n40939837\n40550326\n40268875\n40166057\n40113645\n39521638\n39477497\n39473093\n39318581\n39209284\n38752520\n38672596\n38635050\n37536738\n37432081\n37385221\n37070991\n36215568\n36008120\n35738906\n35625683\n35045552\n34772793\n34446454\n34373733\n34094956\n33509971\n33353867\n32970216\n32685010\n31924729\n31614001\n30552200\n29536496\n", "stderr": "", "elapsed_s": 0.655, "ts": 1771594522.5205896}
{"seq": 10, "variant": "control", "cmd": "pm search PSMA PET MTV prostate cancer prognostic", "exit_code": 0, "stdin_lines": 0, "stdout": "41421031\n40841271\n40137954\n39110196\n38718704\n38711135\n38298510\n37332068\n36261050\n34439287\n34366407\n32948911\n32685010\n", "stderr": "", "elapsed_s": 0.787, "ts": 1771594532.038503}
{"seq": 11, "variant": "control", "cmd": "pm search PSMA PET \"total lesion\" prostate cancer prognos*", "exit_code": 0, "stdin_lines": 0, "stdout": "41703276\n41679922\n41421031\n41276643\n41071425\n41021003\n40935614\n40851054\n40647545\n40318933\n40268875\n40241844\n40137954\n40113645\n39961974\n39881967\n39843627\n39839009\n39080696\n38949389\n38880859\n38835183\n38718704\n38469242\n38453363\n38360991\n38298510\n38007857\n37889298\n37332068\n37272956\n35045552\n34439287\n33866336\n33586097\n32970216\n32948911\n32941400\n", "stderr": "", "elapsed_s": 0.684, "ts": 1771594542.1631837}
{"seq": 12, "variant": "control", "cmd": "pm fetch -v 2", "exit_code": 0, "stdin_lines": 122, "stdout": "<?xml version=\"1.0\" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2025//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd\">\n<PubmedArticleSet>\n<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Manual\"><PMID Version=\"1\">27229485</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">1748-717X</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>11</Volume><PubDate><Year>2016</Year><Month>May</Month><Day>26</Day></PubDate></JournalIssue><Title>Radiation oncology (London, England)</Title><ISOAbbreviation>Radiat Oncol</ISOAbbreviation></Journal><ArticleTitle>Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.</ArticleTitle><Pagination><StartPage>73</StartPage><MedlinePgn>73</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">73</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1186/s13014-016-0646-2</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Prostate cancer (PC) is one of the most commonly treated cancer entities with radiation therapy (RT). Risk group-adapted treatment and avoidance of unnecessary toxicities relies primarily on accurate tumor staging. Thus, the introduction of prostate-specific membrane antigen (PSMA) in diagnosis and treatment of PC is a highly interesting development in radiation oncology of urologic tumors. The present work is to evaluate the integration of (68)Ga-PSMA-PET imaging into standard radiation planning of primary definitive treatment of PC and to determine the impact of PSMA imaging on tumor staging.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">The data of 15 patients treated for PC between August 2013 and April 2015 were evaluated. Treatment planning included (68)Ga-PSMA-PET imaging. We analyzed whe", "stderr": "Fetching batch 1 (122 PMIDs)...\n", "elapsed_s": 1.392, "ts": 1771594571.3795195}
{"seq": 13, "variant": "control", "cmd": "pm fetch -v", "exit_code": 0, "stdin_lines": 122, "stdout": "<?xml version=\"1.0\" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2025//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd\">\n<PubmedArticleSet>\n<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Manual\"><PMID Version=\"1\">27229485</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">1748-717X</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>11</Volume><PubDate><Year>2016</Year><Month>May</Month><Day>26</Day></PubDate></JournalIssue><Title>Radiation oncology (London, England)</Title><ISOAbbreviation>Radiat Oncol</ISOAbbreviation></Journal><ArticleTitle>Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.</ArticleTitle><Pagination><StartPage>73</StartPage><MedlinePgn>73</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">73</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1186/s13014-016-0646-2</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Prostate cancer (PC) is one of the most commonly treated cancer entities with radiation therapy (RT). Risk group-adapted treatment and avoidance of unnecessary toxicities relies primarily on accurate tumor staging. Thus, the introduction of prostate-specific membrane antigen (PSMA) in diagnosis and treatment of PC is a highly interesting development in radiation oncology of urologic tumors. The present work is to evaluate the integration of (68)Ga-PSMA-PET imaging into standard radiation planning of primary definitive treatment of PC and to determine the impact of PSMA imaging on tumor staging.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">The data of 15 patients treated for PC between August 2013 and April 2015 were evaluated. Treatment planning included (68)Ga-PSMA-PET imaging. We analyzed whe", "stderr": "Fetching batch 1 (122 PMIDs)...\n", "elapsed_s": 1.405, "ts": 1771594596.2360191}
{"seq": 14, "variant": "control", "cmd": "pm parse -v", "exit_code": 0, "stdin_lines": 443, "stdout": "{\"pmid\": \"27229485\", \"title\": \"Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.\", \"authors\": [\"Dewes Sabrina\", \"Schiller Kilian\", \"Sauter Katharina\", \"Eiber Matthias\", \"Maurer Tobias\", \"Schwaiger Markus\", \"Gschwend J\u00fcrgen E\", \"Combs Stephanie E\", \"Habl Gregor\"], \"journal\": \"Radiation oncology (London, England)\", \"year\": \"2016\", \"date\": \"2016-05-26\", \"abstract\": \"Prostate cancer (PC) is one of the most commonly treated cancer entities with radiation therapy (RT). Risk group-adapted treatment and avoidance of unnecessary toxicities relies primarily on accurate tumor staging. Thus, the introduction of prostate-specific membrane antigen (PSMA) in diagnosis and treatment of PC is a highly interesting development in radiation oncology of urologic tumors. The present work is to evaluate the integration of (68)Ga-PSMA-PET imaging into standard radiation planning of primary definitive treatment of PC and to determine the impact of PSMA imaging on tumor staging. The data of 15 patients treated for PC between August 2013 and April 2015 were evaluated. Treatment planning included (68)Ga-PSMA-PET imaging. We analyzed whether the use of PSMA-imaging led to a change of the TNM stage and if it influenced the RT treatment approach or the target volume, due to changes in the gross tumor volume (GTV) or clinical target volume (CTV), in the final treatment plan. In 53.3 % of the analyzed patients a change occurred in the TNM stage based on (68)Ga-PSMA-PET examination. The RT concept changed in 33.3 % of all patients, leading to relevant changes in the planning target volume. Among these, an additional irradiation of the pelvic lymph drainage due to tracer uptake in lymph nodes was performed in 25 %. Furthermore, boost volumes of PET-positive lymph nodes were added in 80 % of these cases. A down staging due to the (68)Ga-PSMA-PET examination occurred in 13.3 % of all cases. The integration of (68)Ga-PSMA-PET-imaging into the RT treatment planning process ", "stderr": "Parsed article 1: PMID 27229485\nParsed article 2: PMID 29536496\nParsed article 3: PMID 30363462\nParsed article 4: PMID 30552200\nParsed article 5: PMID 31614001\nParsed article 6: PMID 31924729\nParsed article 7: PMID 32685010\nParsed article 8: PMID 32941400\nParsed article 9: PMID 32948911\nParsed article 10: PMID 32970216\nParsed article 11: PMID 33353867\nParsed article 12: PMID 33509971\nParsed article 13: PMID 33525456\nParsed article 14: PMID 33586096\nParsed article 15: PMID 33586097\nParsed article 16: PMID 33866336\nParsed article 17: PMID 34094956\nParsed article 18: PMID 34326127\nParsed article 19: PMID 34359750\nParsed article 20: PMID 34366407\nParsed article 21: PMID 34373733\nParsed article 22: PMID 34439287\nParsed article 23: PMID 34446454\nParsed article 24: PMID 34772793\nParsed article 25: PMID 35008315\nParsed article 26: PMID 35045552\nParsed article 27: PMID 35422442\nParsed article 28: PMID 35453632\nParsed article 29: PMID 35543629\nParsed article 30: PMID 35625683\nParsed article 31: PMID 35738906\nParsed art", "elapsed_s": 0.418, "ts": 1771594617.9520798}
{"seq": 15, "variant": "control", "cmd": "pm filter --year 2020- --has-abstract -v", "exit_code": 0, "stdin_lines": 122, "stdout": "{\"pmid\": \"31614001\", \"title\": \"Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer.\", \"authors\": [\"Grubm\u00fcller Bernhard\", \"Rasul Sazan\", \"Baltzer Pascal\", \"Fajkovic Harun\", \"D'Andrea David\", \"Berndl Florian\", \"Maj-Hes Agnes\", \"Grubm\u00fcller Karl Hermann\", \"Mitterhauser Markus\", \"Wadsak Wolfgang\", \"Pfaff Sarah\", \"Shariat Shahrokh F\", \"Hacker Marcus\", \"Kramer Gero\", \"Hartenbach Markus\"], \"journal\": \"The Prostate\", \"year\": \"2020\", \"date\": \"2020-01\", \"abstract\": \"To assess which parameters of [68 Ga]Ga-PSMA-11 positron emission tomography (PSMA-PET) predict response to systemic therapies in metastatic (m) castration-resistant prostate cancer (CRPC). In addition, to investigate which of these factors are associated with overall survival (OS). We retrospectively assessed the following PSMA-PET parameters in 43 patients before and after systemic therapies for mCRPC: PSMA total tumor volume (TTV), mean standardized uptake value (SUVmean), SUVmax, and SUVpeak. prostate-specific antigen (PSA) levels and PSMA-PET/CT(magnetic resonance imaging [MRI]) imaging were both performed within 8 weeks before and 6 weeks after systemic therapy. PSMA-PET and CT (MRI) images were reviewed according to the modified PET Response Criteria in Solid Tumors (PERCIST) and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Results were compared to PSA response. Univariable survival analyses were performed. Overall, 43 patients undergoing 67 systemic therapies were included (9 patients radium-223, 12 cabazitaxel, 22 docetaxel, 6 abiraterone, and 18 enzalutamide). Median serum PSA level before any therapy was 11.3\u2009ng/mL (interquartile range [IQR]\u2009=\u20093.3, 30.1). Delta (d) PSA after systemic therapies was -41%, dTTV 10.5%, dSUVmean -7.5%, dSUVmax -13.3%, dSUVpeak -12%, and dRECIST -13.3%. Overall, 31 patients had dPSA response (46.3%), 12 stable disease (17.9%), and 24 progressive disease (35.8%). All observed PET parameters, as well as the RECIST evaluat", "stderr": "118 articles passed filters\n", "elapsed_s": 0.292, "ts": 1771594637.855408}
